Alpha 1 Antitrypsin Deficiency


Article Author:
Marcelle Meseeha


Article Editor:
Maximos Attia


Editors In Chief:
Linda Lindsay


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Trevor Nezwek
Radia Jamil
Erin Hughes
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Beenish Sohail
Nazia Sadiq
Hajira Basit
Phillip Hynes


Updated:
12/14/2018 1:13:21 PM

Introduction

Alpha-1 antitrypsin (AAT) deficiency is a clinically under-recognized genetic disorder that causes the defective production of alpha-1 antitrypsin protein. AAT protein protects the body from the neutrophil elastase enzyme which is released from white blood cells to fight infection. This inherited disorder leads to decreased AAT activity in the blood and lung and deposition of excessive abnormal AAT protein in the liver.

Both deficiency and an abnormal form of AAT are due to mutations in the SERPINA1 gene. Without enough functional AAT, neutrophil elastase destroys alveoli and causes lung disease. Abnormal AAT can also accumulate in the liver and cause damage to this organ. People with AAT deficiency usually develop the first signs and symptoms of lung disease between ages 20 and 50. It is well-documented that the rate of decline in lung function is strongly dependent on cigarette smoking.[1][2][3]

Etiology

AAT deficiency is inherited by the autosomal co-dominant transmission which means that affected individuals have inherited an abnormal AAT gene from each parent. The gene that encodes AAT is called SERPINA1 and is located on the long arm of chromosome 14.

At least 150 alleles of AAT (SERPINA1) have been identified, and each has a letter code based upon electrophoretic mobility of the protein produced. The normal allele is referred to as “M,” and it is the most common version (allele) of the SERPINA1 gene. Most people in the general population have two copies of the M allele (MM) in each cell. Other versions of the SERPINA1 gene lead to reduced levels of alpha-1 antitrypsin. For instance, the S allele produces moderately low levels of this protein, and the Z allele produces very little AAT. Individuals with two copies of the Z allele (ZZ) in each cell are likely to have AAT deficiency. Those with the SZ combination have a higher risk of developing lung diseases (such as emphysema), particularly if they smoke.

Worldwide, it is estimated that 161 million people have one copy of the S or Z allele and one copy of the M allele in each cell (MS or MZ). Individuals with an MS (or SS) combination usually produce enough alpha-1 antitrypsin to protect their lungs. People with MZ alleles have a slightly increased risk of impaired lung or liver function.

AAT phenotypes are based on the electrophoretic mobility of the proteins produced by the various abnormal AAT alleles. Genotyping is performed by identifying specific alleles in DNA.

Based on this, variants of AAT can be categorized into four basic groups: 

  • Normal that is associated with normal levels of AAT and normal function. The family of normal alleles is referred to as M, and the normal genotype is MM.
  • Deficient that is associated with plasma AAT levels less than 35% of the average normal level. The most common deficient allele associated with emphysema is the Z allele, which is carried by about two to three percent of the Caucasian population in the United States.
  • Null alleles that lead to no detectable AAT protein in the plasma. Individuals with the null genotype are the least common and are at risk for the most severe form of associated lung disease but not liver disease.
  • Dysfunctional alleles produce a normal quantity of AAT protein, but the protein does not function properly.

Environmental factors, such as exposure to tobacco smoke, chemicals, and dust, likely impact the severity of alpha-1 antitrypsin deficiency.

Severe deficiency of AAT has a strong risk factor for early-onset emphysema, but not every severely deficient individual would develop emphysema. Risk factors for emphysema include cigarette smoking, dusty occupational exposure, a parental history of chronic-obstructive pulmonary disease (COPD), and a personal history of asthma, chronic bronchitis, or pneumonia.

Epidemiology

AAT deficiency occurs worldwide, but its prevalence varies by population. This disorder affects about one in 1500 to 3500 individuals with European ancestry. It is uncommon in people of Asian descent.

Although AAT deficiency is considered to be rare, estimates that 80,000 to 100,000 individuals in the United States have a severe deficiency of AAT suggest that the disease is under-recognized. It is estimated that more than three million people worldwide have allele combinations associated with severe deficiency of AAT.[4][5]

Pathophysiology

Emphysema in AAT deficiency is considered due to an imbalance between neutrophil elastase in the lung, which destroys elastin, and the elastase inhibitor AAT, which protects against proteolytic degradation of elastin. This mechanism is called a “toxic loss of function.” Specifically, cigarette smoking and infection increase elastase production in the lung, therefore increasing lung degradation. Also, the polymers of “Z” antitrypsin are chemotactic for neutrophils, which may contribute to local inflammation and tissue destruction in the lung.

The pathogenesis of the liver disease is quite different and is called a “toxic gain of function.” The liver disease results from the accumulation within the hepatocyte of un-secreted variant AAT protein. Only those genotypes associated with pathologic polymerization of AAT within the endoplasmic reticulum of hepatocytes produce disease. Most patients are homozygous for the Z allele (i.e., PI*ZZ); liver disease does not occur in null homozygotes who have severe AAT deficiency but no intra-hepatocytic accumulation.

History and Physical

The main clinical manifestation of AAT deficiency is related to the involvement of three separate organs: the lung, the liver, and rarely, the skin.

Clinical presentation of lung diseases namely of emphysema due to AAT deficiency has many features in common with usual COPD. Dyspnea is the most common presenting symptom, and many patients have a cough, sputum production, and wheezing, either chronically or with upper respiratory tract infections. Spontaneous secondary pneumothorax may be the presenting manifestation of AAT deficiency or a complication of the known disease. Bronchiectasis has also been associated with severe deficiency of AAT.

Clinical presentation of extrapulmonary disease in patients with at-risk alleles (e.g., Z, S[iiyama], and M[malton]) may develop adult-onset chronic hepatitis, cirrhosis, or hepatocellular carcinoma.

Other extrapulmonary manifestations of AAT deficiency include necrotizing panniculitis, hot, painful, erythematous nodules or plaques on the thigh or buttocks that are the major dermatologic manifestation of AAT deficiency. Others are systemic vasculitis, psoriasis, urticaria, angioedema and possibly inflammatory bowel disease, intracranial and intra-abdominal aneurysms, fibromuscular dysplasia, and glomerulonephritis.

Evaluation

Imaging: chest x-ray is used to determine the pattern and extent of emphysema and exclude other causes of dyspnea. The “classic” pattern of emphysema in AAT deficiency is basilar predominant emphysematous bullae although a range of patterns from basilar predominant to apical predominant emphysema may be seen. Some clinicians perform chest computed tomography (CT) scans for initial assessment.[6][7]

  • Bronchodilator responsiveness (defined as a post-bronchodilator forced expiratory volume in one second [FEV1] rise of 200 mL and 12%) is common.
  • Pulmonary function testing is used to assess the presence and severity of lung disease. We typically obtain spirometry before and after bronchodilator, lung volumes, and a diffusing capacity for carbon monoxide (DLCO). If DLCO is below normal or if the patient reports exertional dyspnea, a six-minute walk test should be obtained.
  • All adults with persistent airflow obstruction on spirometry should be tested for AAT deficiency, mainly those from geographic areas with a high prevalence of AAT deficiency.

Additional features that should lead clinicians to test for AAT deficiency include:

  • Emphysema in a young individual (e.g., age 45 years or older).
  • Emphysema in a nonsmoker or minimal smoker
  • Emphysema characterized by predominant basilar changes on the chest radiograph
  • A family history of emphysema and/or liver disease. Clinical findings or history of panniculitis
  • Clinical findings or history of unexplained chronic liver disease.

The diagnosis of severe AAT deficiency is confirmed by demonstrating a serum level below 11 micromols/L (approximately 57 mg/dL by nephelometry) in combination with a severe deficient phenotype assessed by testing for the most common deficient alleles (i.e., S, Z, I, F).

If the AAT serum level is greater than 20 micromol/L (80 mg/dL), it is unlikely that the patient has clinically significant AAT deficiency, but if we are evaluating for the presence of particular mutations, genotyping is necessary to identify heterozygotes and mutations that have incomplete penetrance. 

The normal plasma concentration of AAT ranges from 80 mg/dL to 220 mg/dL (20 to 48 micromol/L using nephelometry or 150 mg/dL to 350 mg/dL by radial immunodiffusion). However, given the variability in reference ranges, patients with a serum AAT level below 100 mg/dL (18.4 micromols/L) should be evaluated further with isoelectric focusing or genotyping.

Isoelectric focusing is the gold standard blood test for identifying AAT variants and is considered a phenotype test.

Genotyping of the protease inhibitor (Pi) locus is performed on a blood sample using polymerase chain reaction (PCR) technology or restriction fragment length polymorphisms. These tests detect the most common known variants (F, I, S, Z). Gene sequencing of exonic DNA can be used if both tests fail to determine the genetic variant.

In monitoring asymptomatic patients, i.e., those with no respiratory symptoms and a normal baseline spirometry (i.e., FEV1 80% or greater of predicted), a spirometry should be repeated when symptoms change or at 6 to 12-month intervals. An unexplained decrease in the post-bronchodilator FEV1 to less than 805 predicted is an indication to initiate augmentation therapy.

Guidelines are lacking regarding monitoring for liver disease in patients homozygous for PiZ, PiS[iiyama] or PiM[malton]. It is advised to assess serum aminotransferases, alkaline phosphatase, and bilirubin on an annual basis. Some clinicians also obtain a complete blood count (CBC), looking for thrombocytopenia, and an abdominal ultrasound looking for cirrhosis every 6 to 12 months.

Treatment / Management

Intravenous augmentation via the infusion of pooled human alpha-1 antitrypsin which is alpha-1 proteinase inhibitor. This therapy is the most direct and efficient means of elevating AAT levels in the plasma and the lung interstitium. [8][9][10][11]

The American Thoracic Society suggests weekly augmentation therapy with human pooled AAT for individuals who have plasma levels of AAT less than 11 micromols/L and established airflow obstruction, defined as a FEV1 less than 80% predicted. On the other hand, the Canadian Thoracic Society suggests keeping AAT augmentation therapy for AAT-deficient patients (AAT level less than 11 micromols/L) with a FEV1 of 25% to 80% predicted who have quit smoking and are on optimal medical therapy.

The selection criteria for augmentation therapy include:

  • High-risk phenotype
  • Plasma AAT level below 11 micromols/L
  • Airflow obstruction by spirometry (e.g., FEV1 less than 80% of predicted)
  • Likely compliance with the protocol
  • Age equal to or greater than 18 years
  • Nonsmoker or ex-smoker.

Augmentation therapy is not recommended for patients with heterozygous phenotypes whose plasma AAT level exceeds 11 micromols/L.

Side effects associated with IV AAT infusion are uncommon, and no long-term reactions have been noted. Some side effects can occur including:

  • Low-grade fever and mild flu-like symptoms are usually self-limited
  • Anaphylaxis with IgE antibody formation to AAT has been reported, and that is extremely rare
  • A syndrome of transient fever, chest and low back pain, and thrombocytopenia has been reported. It is due to a high molecular weight contaminant in the stabilizer added to the AAT product in the late 1980s
  • Pooled human plasma alpha 1-antiprotease contains small amounts of IgA so that IgA-deficient individuals with anti-IgA antibodies are at risk of anaphylaxis with current infusions. Before initiating intravenous AAT therapy, it is recommended to check for IgA deficiency or anti-IgA antibodies.

Enhancing Healthcare Team Outcomes

AAT is best managed by a multidisciplinary team of health professionals that includes a pediatrician, geneticist, pulmonologist, a gastroenterologist and an internist. During the first three decades of life: liver dysfunction is the major threat to the health of affected individuals, and pulmonary dysfunction is not a major concern. Beyond the first two to three decades of life, the natural history of individuals with severe deficiency of AAT is less clear, and survival estimates for subjects with severe deficiency of AAT vary among series, presumably due to differences in study populations. Relatively normal survival appears possible for nonsmoking asymptomatic individuals although long-term follow-up in a population-based study is needed for confirmation. The FEV1 is a major determinant of survival in AAT-deficient individuals, with the mortality rising considerably as FEV1 falls below 35% of predicted. Other parameters that are used to predict include decreased lung density as assessed by chest CT.[12][13]


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Alpha 1 Antitrypsin Deficiency - Questions

Take a quiz of the questions on this article.

Take Quiz
Which of the following is false about alpha-1-antitrypsin deficiency syndrome?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 32-year-old presents with vague abdominal pain and nausea. He remains jaundiced and a liver biopsy reveals hyaline droplets varying in size, which are periodic acid–Schiff (PAS) positive and diastase negative granules. What condition does this patient most likely have?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following is associated with alpha-1-antitrypsin deficiency?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 48-year-old woman has never consumed alcohol but has smoked for 20 years. She has developed early cirrhosis and chronic obstructive pulmonary disease. Studies show the patient is homozygous for the Z allele of alpha-1-antitrypsin. This is a missense mutation preventing the proper folding of this protein. A liver biopsy shows subcellular deposition of a proteinaceous substance. What is the location of this accumulation?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following is often seen a 33-year-old with alpha-1 antitrypsin deficiency?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which feature is not associated with worsening of alpha 1 antitrypsin deficiency?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which is false about alpha 1 antitrypsin?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which is a true statement regarding alpha-1 antitrypsin deficiency?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What unusual and rare form of COPD has a familial inheritance?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is the most common cause of the inherited form of emphysema?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which is true of alpha 1-antitrypsin (AAT) deficiency?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following statements about alpha-1-antitrypsin deficiency is false?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 35-year-old man was referred to the pulmonary clinic with gradual onset of shortness of breath. It is associated with an intermittent cough and phlegm for most of the days. He has a history of hypertension and diabetes mellitus. He is a smoker of 10 pack years. Pulmonary function test ( PFT) showed FEV1 of 1.58 L which is 60 percent of predicted. Chest x-ray showed flattened diaphragm with lower lobe emphysema. What test should be ordered next to aid his diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Patients with alpha 1 antitrypsin (AAT) deficiency are at increased risk of developing emphysema. AAT is a serum protein made in the liver. What does it inactivate?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Alpha 1 Antitrypsin Deficiency - References

References

Hersh CP,Campbell EJ,Scott LR,Raby BA, Alpha1-Antitrypsin Deficiency as an Incidental Finding in Clinical Genetic Testing. American journal of respiratory and critical care medicine. 2018 Oct 25     [PubMed]
Tasch JJ,McLaughlan AT,Nasir AA, A Novel Approach to Screening for Alpha-1 Antitrypsin Deficiency: Inpatient Testing at a Teaching Institution. Chronic obstructive pulmonary diseases (Miami, Fla.). 2018 Apr 1     [PubMed]
Gramegna A,Aliberti S,Confalonieri M,Corsico A,Richeldi L,Vancheri C,Blasi F, Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement. Multidisciplinary respiratory medicine. 2018     [PubMed]
Curjuric I,Imboden M,Bettschart R,Caviezel S,Dratva J,Pons M,Rothe T,Schmidt-Trucksäss A,Stolz D,Thun GA,von Eckardstein A,Kronenberg F,Ferrarotti I,Probst-Hensch NM, Alpha-1 antitrypsin deficiency: From the lung to the heart? Atherosclerosis. 2018 Mar     [PubMed]
McCarthy C,Lara Gallego B,Trapnell BC,McCormack FX, Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge. Advances in experimental medicine and biology. 2017     [PubMed]
Patel D,Teckman JH, Alpha-1-Antitrypsin Deficiency Liver Disease. Clinics in liver disease. 2018 Nov     [PubMed]
Torres-Durán M,Lopez-Campos JL,Barrecheguren M,Miravitlles M,Martinez-Delgado B,Castillo S,Escribano A,Baloira A,Navarro-Garcia MM,Pellicer D,Bañuls L,Magallón M,Casas F,Dasí F, Alpha-1 antitrypsin deficiency: outstanding questions and future directions. Orphanet journal of rare diseases. 2018 Jul 11     [PubMed]
Miravitlles M,Dirksen A,Ferrarotti I,Koblizek V,Lange P,Mahadeva R,McElvaney NG,Parr D,Piitulainen E,Roche N,Stolk J,Thabut G,Turner A,Vogelmeier C,Stockley RA, European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α{sub}1{/sub}-antitrypsin deficiency. The European respiratory journal. 2017 Nov     [PubMed]
Luna Diaz LV,Iupe I,Zavala B,Balestrini KC,Guerrero A,Holt G,Calderon-Candelario R,Mirsaeidi M,Campos M, Improving adherence to alpha-1 antitrypsin deficiency screening guidelines using the pulmonary function laboratory. International journal of chronic obstructive pulmonary disease. 2017     [PubMed]
Campos M,Lascano J, Therapeutics: Alpha-1 Antitrypsin Augmentation Therapy. Methods in molecular biology (Clifton, N.J.). 2017     [PubMed]
Kueppers F,Sanders C, State-of-the-art testing for alpha-1 antitrypsin deficiency. Allergy and asthma proceedings. 2017 Mar 24     [PubMed]
Wilke A,Semper H,Gross C,Grohé C, [Longterm Homecare Augmentation Program in Alpha-1-Antitrypsin Deficient Patients]. Pneumologie (Stuttgart, Germany). 2018 Aug     [PubMed]
Stockley RA,Edgar RG,Starkey S,Turner AM, Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies? Respiratory research. 2018 Jul 20     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of NP-Genetics. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for NP-Genetics, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in NP-Genetics, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of NP-Genetics. When it is time for the NP-Genetics board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study NP-Genetics.